Immutep Limited IMMP · NASDAQ
$3.20 -0.31% (-$0.01)
Summary
46 / 100 · Bulios Score
What speaks for it
- Revenue grew by 60% a year over the last 3 years.
- It holds more cash than debt: $68.9M against $1.05M.
What to watch
- The company made a loss over the last 12 months.
- The price moves much more than the market (beta 2.31).
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (AUD)
Diluted EPS (AUD)
- Analyst estimate
Revenue grew by 30% a year over 5 years. Over the last 3 years it grew by 60% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $4.25 is 33% above today's price. 50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.